Walvax Biotechnology Co Ltd (300142):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Walvax Biotechnology Co Ltd (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8224
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Walvax Biotechnology Co Ltd (Walvax) is a biopharmaceutical company that develops, produces and markets bio-medical products including vaccines and blood products. The company’s products include haemophilus influenzae vaccine for the prevention of infectious diseases such as meningitis. Walvax offers drugs for pneumonia, septicemia, cellulitis, arthritis and epiglottitis. It offers Group A, C meningococcal polysaccharide vaccine for preventing diseases such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine to prevent meningococcal disease. The company markets its products through a distribution network in China. The company operates a research and development center in Kunming. Walvax is headquartered in Kunming, China.

Walvax Biotechnology Co Ltd (300142) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
MabSpace Biosciences Enters into Agreement with Genor Biopharma 11
Licensing Agreements 12
Genor Biopharm Enters into Licensing Agreement with NewBio Therapeutics 12
Genor BioPharma Enters Into Licensing Agreement With BioCND For Biosimilars 13
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 14
Equity Offering 15
Walvax Biotech Raises USD89 Million in Private Placement of Shares 15
Genor BioPharma Raises USD81.8 Million in Private Placement 16
Walvax Biotech Raises USD72.9 Million in Private Placement of Shares 17
Debt Offering 18
Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million 18
Walvax Biotechnology Plans Debt Offering For US$398 Million 19
Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million 20
Acquisition 21
Walvax Biotech Plans to Sell Stake in Shanghai-based Pharma-Tech for USD15.4 Million 21
Tianjin-based Limited Partnership Plans to Acquire 11.3% Stake in Walvax Biotechnology 22
Walvax Biotech to Sell 85% Stake in Shandong Shijie Biological Technology for USD104.5 Million 23
Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million 24
Walvax Biotech to Sell 46% Stake in Hebei Da’an Pharma for USD103 Million 25
Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million 26
Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million 27
Walvax Biotechnology Acquires 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group for USD47.5 Million 28
Walvax Biotech Acquires Three Biomedical Companies 30
Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million 31
Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million 32
Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million 33
Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million 34
Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da’an Pharma For US$54.6 Million 35
Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million 36
Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da’an Pharma For Up To US$84 Million 37
Walvax Biotechnology Co Ltd – Key Competitors 38
Walvax Biotechnology Co Ltd – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Walvax Biotechnology Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MabSpace Biosciences Enters into Agreement with Genor Biopharma 11
Genor Biopharm Enters into Licensing Agreement with NewBio Therapeutics 12
Genor BioPharma Enters Into Licensing Agreement With BioCND For Biosimilars 13
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 14
Walvax Biotech Raises USD89 Million in Private Placement of Shares 15
Genor BioPharma Raises USD81.8 Million in Private Placement 16
Walvax Biotech Raises USD72.9 Million in Private Placement of Shares 17
Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million 18
Walvax Biotechnology Plans Debt Offering For US$398 Million 19
Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million 20
Walvax Biotech Plans to Sell Stake in Shanghai-based Pharma-Tech for USD15.4 Million 21
Tianjin-based Limited Partnership Plans to Acquire 11.3% Stake in Walvax Biotechnology 22
Walvax Biotech to Sell 85% Stake in Shandong Shijie Biological Technology for USD104.5 Million 23
Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million 24
Walvax Biotech to Sell 46% Stake in Hebei Da'an Pharma for USD103 Million 25
Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million 26
Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million 27
Walvax Biotechnology Acquires 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group for USD47.5 Million 28
Walvax Biotech Acquires Three Biomedical Companies 30
Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million 31
Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million 32
Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million 33
Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million 34
Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da'an Pharma For US$54.6 Million 35
Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million 36
Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da'an Pharma For Up To US$84 Million 37
Walvax Biotechnology Co Ltd, Key Competitors 38
Walvax Biotechnology Co Ltd, Subsidiaries 39

List of Figures
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Walvax Biotechnology Co Ltd (300142):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CarrefourSA A.S. (CRFSA):企業の財務・戦略的SWOT分析
    CarrefourSA A.S. (CRFSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Meiji Co Ltd:企業の戦略・SWOT・財務情報
    Meiji Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Meiji Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • IXICO Plc (IXI):企業の財務・戦略的SWOT分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints and assessing the safety and efficacy of drugs. The company offers products such as Assessa and trial tracker. Assessa provides web-based platform to tra …
  • Molecular Warehouse Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Molecular Warehouse Ltd (Molecular Warehouse) is a developer of proteins for diagnostic and therapeutic use. The company helps prevent diseases by empowering people with molecular diagnostics. Its synthetic biology techniques enabled it to reengineer glucose dehydrogenase, and enzymes found …
  • SBM Offshore NV (SBMO):企業の財務・戦略的SWOT分析
    SBM Offshore NV (SBMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Olink Proteomics AB:企業の製品パイプライン分析
    Summary Olink Proteomics AB (Olink) is a biotechnology company that offers products and services for human protein biomarker research. The company provides portfolio of products such as biomarkers, cardiovascular diseases panels, neurological disease panels, inflammation panels and oncology panels. …
  • Onex Corporation:企業の戦略・SWOT・財務情報
    Onex Corporation - Strategy, SWOT and Corporate Finance Report Summary Onex Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • LipimetiX Development Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary LipimetiX Development Inc (LipimetiX), formerly LipimetiX LLC is a biopharmaceutical company that develops drugs to treat refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases. The company develops drugs based on chimeri …
  • Imbed Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Imbed Biosciences Inc (Imbed) is a medical device company that develops technologies for imbedding bioactive molecules in wound dressings and surgical implants. The company’s polymeric microfilm product platform develops bioactive molecules on tissue surfaces to manage wound infections, biof …
  • Junex Inc (JNX):企業の財務・戦略的SWOT分析
    Junex Inc (JNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • St. Jude Medical, Inc.:企業のM&A・事業提携・投資動向
    St. Jude Medical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's St. Jude Medical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Powerco Ltd:発電所・企業SWOT分析
    Powerco Ltd – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Quad/Graphics, Inc.:企業の戦略・SWOT・財務分析
    Quad/Graphics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Quad/Graphics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Dalton Pharma Services-製薬・医療分野:企業M&A・提携分析
    Summary Dalton Pharma Services (Dalton) is a contract manufacturing company that offers discovery, development and contract manufacturing services. The company’s product categories include building blocks, coelenterazines, drugs and metabolites, glitazones, gmp APIs, excipients and reagents, heteroc …
  • Waste Management Inc (WM):企業の財務・戦略的SWOT分析
    Waste Management Inc (WM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cboe Global Markets, Inc (CBOE):企業の財務・戦略的SWOT分析
    Cboe Global Markets, Inc (CBOE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • KCC Corp (002380):企業の財務・戦略的SWOT分析
    KCC Corp (002380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • SynteractHCR Inc-製薬・医療分野:企業M&A・提携分析
    Summary SynteractHCR Inc (SynteractHCR), a subsidiary of Amulet Capital Partners LP is a contract research organization that offers clinical trials support services. The organization provides phase I – IV clinical development services, clinical services, vendor management, study document development …
  • Innospec Inc. (IOSP):石油・ガス:M&Aディール及び事業提携情報
    Summary Innospec Inc (Innospec) is a provider of specialty chemicals. It blends, manufactures and supplies fuel additives and other specialty chemicals. Innospec’s product portfolio includes stabilizers, detergents, cold flow improvers, lubricity improvers, corrosion inhibitors, conductivity improve …
  • Core-Mark Holding Company, Inc. (CORE):企業の財務・戦略的SWOT分析
    Core-Mark Holding Company, Inc. (CORE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆